SAH Clinical Trial
Official title:
Atorvastatin Effect in Incidence and Ischemic Complications of Vasospasm After Subarachnoid Aneurysmal Hemorrhage: a Cohort Study
The 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors, known as statins, have recently been demonstrated to improve endothelial function. Additionally, numerous studies have shown statins as having antiinflammatory and cell-signaling effects together with a selective up-regulation of the eNOS activity. These findings are of potential benefit for the prevention of cerebral vasospasm after a aneurysmal subarachnoid hemorrhage. Indeed, one of the possible mechanisms for this vasospasm is the eNOS depletion or even increase of eNOS expression after the hemorrhage. The purpose of this study is to observe the immediate effect of statins after aneurysmal subarachnoid hemorrhage (aSAH) in cerebral vasospasm and outcome at one year.
Up to now, the preventive and curative treatment of vasospasm secondary to subarachnoid
aneurismal hemorrhage has been based on three major approaches: increasing arterial pressure
and cerebral blood flow with the use of triple H therapy, increasing the ischemic threshold
of neurons with nimodipine and reopening proximal arteries with angioplasty and/or
intra-arterial administration of nimodipine, verapamil, milrinone or papaverine. Recently,
several teams have observed the efficacy of diverse statins in the prevention of vasospasm
by improving the imbalance between the nitric oxide and the endothelin pathways, a major
actor in the physiopathology of vasospasm. Indeed, this family of molecules improve the
bioavailability of endogenous nitric oxide and upregulate the endothelial NO synthase.
In humans, statin administered within the first 72 hours showed to significantly reduce the
incidence of vasospasm up to 50% an therefore, induce a lower morbidity and mortality of
this severely ill population. The aim of this study is to demonstrate that atorvastatin
reduces the incidence of cerebral vasospasm-related morbidity and mortality within 1 year
post aneurysmal subarachnoid hemorrhage (aSAH) treated by either clipping or endovascular
coiling.
;
Observational Model: Cohort, Time Perspective: Prospective
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT03754725 -
Ferritin and Iron Burden in SAH sIRB
|
Phase 1/Phase 2 | |
Completed |
NCT01556620 -
Is NIRS Able to Detect Ischemia Following Brain Insult
|
N/A | |
Completed |
NCT01832389 -
Goal Directed Therapy After Aneurysmal Subarachnoid Haemorrhage
|
N/A | |
Completed |
NCT04988932 -
Inhaled Nitric Oxide Treatment for Aneurysmal SAH Patients With Intractable Cerebral Vasospasm
|
N/A | |
Completed |
NCT01656317 -
Rehabilitation of Patients After Subarachnoid Hemorrhage
|
N/A | |
Terminated |
NCT01343537 -
Continuous Neurophysiological Monitoring Detection of Cerebral Vasospasm in Aneurysmal Subarachnoid Hemorrhage Subjects
|
Phase 0 |